Rouzioux Christine, Hubert Jean-Baptiste, Burgard Marianne, Deveau Christiane, Goujard Cécile, Bary Marc, Séréni Daniel, Viard Jean-Paul, Delfraissy Jean-François, Meyer Laurence
Laboratoire de Virologie, Paris, France.
J Infect Dis. 2005 Jul 1;192(1):46-55. doi: 10.1086/430610. Epub 2005 May 31.
The objective of this work was to assess the role of human immunodeficiency virus (HIV) reservoirs in the risk of disease progression, by studying the relationship between HIV DNA level in peripheral blood mononuclear cells (PBMCs) and progression toward acquired immunodeficiency syndrome (AIDS).
HIV-1 DNA levels in PBMCs were determined by quantitative polymerase chain reaction for 383 patients enrolled in the SEROCO Cohort Study who had experienced seroconversion and had been followed up for >8 years. We compared the predictive values of HIV DNA level, HIV RNA level, and CD4+ cell count.
Between 6 and 24 months after seroconversion, HIV DNA level was a major predictor of progression to AIDS independently of HIV RNA level and CD4+ T cell count (adjusted relative risk [RR] for a 1-log(10) increase, 3.20 [95% confidence interval {CI}, 1.70-6.00]). HIV DNA level was also a major predictor of disease progression during the first 6 months after seroconversion (adjusted RR, 4.16 [95% CI, 1.70-10.21]), when HIV RNA level and CD4+ T cell count were less predictive. Thus, a combination of these 3 markers provides the best estimate of the risk of disease progression for each patient.
Our results suggest that HIV DNA level could be a useful additional marker in clinical practice and could aid in helping to define the best time to initiate treatment for each patient.
本研究旨在通过研究外周血单核细胞(PBMC)中HIV DNA水平与获得性免疫缺陷综合征(AIDS)进展之间的关系,评估HIV储存库在疾病进展风险中的作用。
采用定量聚合酶链反应测定了参与SEROCO队列研究的383例血清转化患者的PBMC中HIV-1 DNA水平,这些患者均已接受超过8年的随访。我们比较了HIV DNA水平、HIV RNA水平和CD4+细胞计数的预测价值。
在血清转化后6至24个月之间,HIV DNA水平是进展为AIDS的主要预测指标,独立于HIV RNA水平和CD4+ T细胞计数(每增加1个对数(10)的调整相对风险[RR]为3.20[95%置信区间{CI},1.70 - 6.00])。在血清转化后的前6个月,当HIV RNA水平和CD4+ T细胞计数的预测性较低时,HIV DNA水平也是疾病进展的主要预测指标(调整RR为4.16[95% CI,1.70 - 10.21])。因此,这3个标志物的组合可为每位患者的疾病进展风险提供最佳估计。
我们的结果表明,HIV DNA水平可能是临床实践中一个有用的附加标志物,有助于确定每位患者开始治疗的最佳时机。